Loading clinical trials...
Loading clinical trials...
Phase I, Randomized, Observer-blinded, 3-part, Dose Escalation and Expanded Safety and Dose Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1
Conditions
Interventions
BNT163
Placebo
Locations
6
United States
Alliance for Multispecialty Research, LLC
Tempe, Arizona, United States
Great Lakes Clinical Trials - Flourish Research
Chicago, Illinois, United States
Accellacare Raleigh Medical Group
Raleigh, North Carolina, United States
Accellacare PMG Research Wilmington LLC
Wilmington, North Carolina, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
December 8, 2022
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
October 20, 2025
NCT06698575
NCT02030301
NCT02300142
NCT02114060
Lead Sponsor
BioNTech SE
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions